Ryoncil (remestemcel-L-rknd) - MEDICAID - FLORIDA

This policy covers Ryoncil (remestemcel‑L‑rknd) intravenous treatment for steroid‑refractory acute graft‑versus‑host disease (aGVHD) after allogeneic hematopoietic cell transplantation, primarily in pediatric patients. Coverage is limited to individuals 2 months–17 years with documented steroid resistance (disease progression within 3 days or no improvement within 7 days on ≥2 mg/kg/day methylprednisolone or equivalent), required IBMTR grading and organ‑specific severity thresholds, prior medical‑director review, dosing of twice weekly for 4 weeks, exclusion of pregnant/breastfeeding patients, and verification that other causes of symptoms (eg, infectious diarrhea) have been ruled out.

"Grade A | Stage 1 skin involvement (extent of rash, less than 25%)"

Sign up to see full coverage criteria, indications, and limitations.